\-\ Texto\\:\\ \ \(0\)\
\-\ some\\ decreased\\ respiratory\\ effort\\ and\\ shortness\\ of\\ air\\.\\ \\ no\\ consolidation\\ appreciated\\.\ \(0\)\
\-\ esr\\-\\ 49\\ \\(0\\-20\\)\ \(0\)\
\-\ crp\\-\\ 9\\ \\(0\\-0\\.9\\)\ \(0\)\
\-\ blastomyces\\ dermatitidis\\ ag\\ 2\\.66\\ \\(2\\.1\\ \\â\\€\\“\\ 4\\ considered\\ positive\\)\ \(0\)\
\-\ treatment\\ usually\\ includes\\ amphotericin\\ b\\ or\\ one\\ of\\ the\\ azole\\ drugs\\,\\ which\\ is\\ normally\\ itraconazole\\.\\ \\ some\\ factors\\ influencing\\ treatment\\ include\\ 1\\)\\ the\\ clinical\\ form\\ and\\ severity\\ of\\ the\\ disease\\ and\\ 2\\)\\ the\\ immune\\ status\\ of\\ the\\ patient\\.\\ \\ if\\ the\\ infection\\ is\\ severe\\,\\ in\\ the\\ cns\\,\\ or\\ systemic\\,\\ a\\ lipid\\ formulation\\ of\\ amphotericin\\ b\\ is\\ preferred\\.\\ \\ if\\ the\\ disease\\ state\\ is\\ mild\\ or\\ moderate\\ and\\ excludes\\ the\\ cns\\,\\ then\\ itraconazole\\ is\\ the\\ drug\\ of\\ choice\\.\ \(0\)\
\-\ if\\ the\\ patient\\ is\\ immunocompetent\\ and\\ presents\\ with\\ an\\ acute\\ infection\\,\\ they\\ may\\ not\\ require\\ treatment\\ at\\ all\\.\\ \\ if\\ there\\ is\\ any\\ possibility\\ of\\ an\\ immunocompromised\\ state\\,\\ then\\ amphotericin\\ b\\ should\\ be\\ promptly\\ administered\\.\ \(0\)\
\-\ \\â\\€\\¢\\ chest\\ pa\\/lateral\\ \\-\\ normal\ \(0\)\
\-\ \\â\\€\\¢\\ ct\\ chest\\ w\\/o\\ contrast\\ \\-\\ \\ cavitary\\ left\\ lower\\ lobe\\ nodule\\ with\\ evidence\\ of\\ endobronchial\\ spread\\.\ \(0\)\
\-\ pulmonary\\ blastomycosis\ \(1\)\
\-\ acute\\ pulmonary\\ blastomycosis\\ may\\ be\\ initially\\ diagnosed\\ as\\ community\\-acquired\\ pneumonia\\.\\ \ \(0\)\
\-\ chronic\\ blastomycosis\\ is\\ often\\ misdiagnosed\\ as\\ tuberculosis\\ or\\ malignancy\\.\\ \ \(0\)\
\-\ sarcoidosis\\ and\\ primary\\ pulmonary\\ lymphoma\\ are\\ possibilities\\.\\ \\ \ \(0\)\
\-\ any\\ skin\\ lesions\\ may\\ be\\ mistaken\\ for\\ pyoderma\\ gangrenosum\\ or\\ keratoacanthoma\\.\ \(0\)\
\-\ 30\\ year\\ old\\ woman\\ presents\\ with\\ shortness\\ of\\ air\\ and\\ one\\ week\\ history\\ of\\ cough\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ blastomycosis\\:\\ 0\\.08695706677102766\ \(0\)\
\-\ amphotericin\\:\\ 0\\.08013432625542402\ \(0\)\
\-\ itraconazole\\:\\ 0\\.05684453065220811\ \(0\)\
\-\ b\\:\\ 0\\.05098767950866395\ \(0\)\
\-\ state\\:\\ 0\\.040730247910567285\ \(0\)\
\-\ if\\:\\ 0\\.03913491027477865\ \(0\)\
\-\ esr\\-\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ 0\\-0\\.9\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ blastomyces\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ dermatitidis\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ 2\\.66\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ influencing\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ pyoderma\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ gangrenosum\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ cns\\:\\ 0\\.0369018326369298\ \(0\)\
\-\ crp\\-\\:\\ 0\\.034271608621968576\ \(0\)\
\-\ azole\\:\\ 0\\.034271608621968576\ \(0\)\
\-\ formulation\\:\\ 0\\.032560785381005854\ \(0\)\
\-\ community\\-acquired\\:\\ 0\\.032560785381005854\ \(0\)\
\-\ keratoacanthoma\\:\\ 0\\.032560785381005854\ \(0\)\
\-\ pulmonary\\:\\ 0\\.03160190266101346\ \(0\)\
\-\ 0\\-20\\:\\ 0\\.031346936974036316\ \(0\)\
\-\ misdiagnosed\\:\\ 0\\.031346936974036316\ \(0\)\
\-\ immunocompetent\\:\\ 0\\.030405403002246402\ \(0\)\
\-\ pa\\/lateral\\:\\ 0\\.030405403002246402\ \(0\)\
\-\ shortness\\:\\ 0\\.030338924885132262\ \(0\)\
\-\ excludes\\:\\ 0\\.02898568892367588\ \(0\)\
\-\ promptly\\:\\ 0\\.026373709141371143\ \(0\)\
\-\ ag\\:\\ 0\\.026061017275743625\ \(0\)\
\-\ immunocompromised\\:\\ 0\\.025769908113351423\ \(0\)\
\-\ then\\:\\ 0\\.02566216775039738\ \(0\)\
\-\ endobronchial\\:\\ 0\\.0254975936781718\ \(0\)\
\-\ possibilities\\:\\ 0\\.025241793586119332\ \(0\)\
\-\ lipid\\:\\ 0\\.024556059706381885\ \(0\)\
\-\ air\\:\\ 0\\.024398840730396335\ \(0\)\
\-\ effort\\:\\ 0\\.024350194034780906\ \(0\)\
\-\ 2\\.1\\:\\ 0\\.024350194034780906\ \(0\)\
\-\ immune\\:\\ 0\\.0239663468693559\ \(0\)\
\-\ may\\:\\ 0\\.023725675555672454\ \(0\)\
\-\ mistaken\\:\\ 0\\.02361452573459197\ \(0\)\
\-\ any\\:\\ 0\\.022707468633521462\ \(0\)\
\-\ cavitary\\:\\ 0\\.02244308380801695\ \(0\)\
\-\ some\\:\\ 0\\.021898128724614\ \(0\)\
\-\ treatment\\:\\ 0\\.02189388556456819\ \(0\)\
\-\ preferred\\:\\ 0\\.021425522386848646\ \(0\)\
\-\ or\\:\\ 0\\.02112917191906556\ \(0\)\
\-\ infection\\:\\ 0\\.020962165182049002\ \(0\)\
\-\ administered\\:\\ 0\\.020775097577450934\ \(0\)\
\-\ w\\/o\\:\\ 0\\.020365123955283643\ \(0\)\
\-\ 49\\:\\ 0\\.01999148092852649\ \(0\)\
\-\ drugs\\:\\ 0\\.01992056481748691\ \(0\)\
\-\ severity\\:\\ 0\\.01958283187371671\ \(0\)\
\-\ one\\:\\ 0\\.01954203698996324\ \(0\)\
\-\ is\\:\\ 0\\.018980279439146854\ \(0\)\
\-\ choice\\:\\ 0\\.018654300714320924\ \(0\)\
\-\ drug\\:\\ 0\\.018500850738916386\ \(0\)\
\-\ possibility\\:\\ 0\\.01820974157652419\ \(0\)\
\-\ consolidation\\:\\ 0\\.018071387893726757\ \(0\)\
\-\ acute\\:\\ 0\\.017804888853219368\ \(0\)\
\-\ normally\\:\\ 0\\.01776518243872745\ \(0\)\
\-\ appreciated\\:\\ 0\\.017559316767126475\ \(0\)\
\-\ spread\\:\\ 0\\.017440452307351383\ \(0\)\
\-\ chest\\:\\ 0\\.01725509704689889\ \(0\)\
\-\ systemic\\:\\ 0\\.017249496224701084\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.01717546960170147\ \(0\)\
\-\ form\\:\\ 0\\.01685753948675722\ \(0\)\
\-\ be\\:\\ 0\\.0166804648524548\ \(0\)\
\-\ require\\:\\ 0\\.01649891833556147\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.01628561757960016\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.016226603900381845\ \(0\)\
\-\ factors\\:\\ 0\\.016197403719603053\ \(0\)\
\-\ \\-\\:\\ 0\\.01545762412412121\ \(0\)\
\-\ \\)\\:\\ 0\\.015053537808297575\ \(0\)\
\-\ respiratory\\:\\ 0\\.014969030653599873\ \(0\)\
\-\ 9\\:\\ 0\\.014904281414466284\ \(0\)\
\-\ pneumonia\\:\\ 0\\.014904281414466284\ \(0\)\
\-\ nodule\\:\\ 0\\.014861660756295383\ \(0\)\
\-\ presents\\:\\ 0\\.01473117548951836\ \(0\)\
\-\ initially\\:\\ 0\\.014675022549642109\ \(0\)\
\-\ considered\\:\\ 0\\.014555031261369816\ \(0\)\
\-\ includes\\:\\ 0\\.014535360319995085\ \(0\)\
\-\ moderate\\:\\ 0\\.01417804771564893\ \(0\)\
\-\ malignancy\\:\\ 0\\.01393286783882496\ \(0\)\
\-\ 30\\:\\ 0\\.013865355850021412\ \(0\)\
\-\ skin\\:\\ 0\\.013848645296366995\ \(0\)\
\-\ cough\\:\\ 0\\.013815421429569923\ \(0\)\
\-\ diagnosed\\:\\ 0\\.013258207412637153\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.013223749802496942\ \(0\)\
\-\ they\\:\\ 0\\.012991333867035045\ \(0\)\
\-\ status\\:\\ 0\\.01287057941426858\ \(0\)\
\-\ week\\:\\ 0\\.012244790794633873\ \(0\)\
\-\ disease\\:\\ 0\\.01178681469380341\ \(0\)\
\-\ positive\\:\\ 0\\.01169993919951104\ \(0\)\
\-\ often\\:\\ 0\\.01150410779966098\ \(0\)\
\-\ should\\:\\ 0\\.011494550809657384\ \(0\)\
\-\ clinical\\:\\ 0\\.011094134177493688\ \(0\)\
\-\ severe\\:\\ 0\\.011094134177493688\ \(0\)\
\-\ usually\\:\\ 0\\.010949064362307\ \(0\)\
\-\ as\\:\\ 0\\.010907827053958883\ \(0\)\
\-\ decreased\\:\\ 0\\.010720491150736536\ \(0\)\
\-\ primary\\:\\ 0\\.010680946256943866\ \(0\)\
\-\ lymphoma\\:\\ 0\\.010304635588141289\ \(0\)\
\-\ all\\:\\ 0\\.010197989406883082\ \(0\)\
\-\ chronic\\:\\ 0\\.010156074400451475\ \(0\)\
\-\ include\\:\\ 0\\.010114571679452686\ \(0\)\
\-\ 4\\:\\ 0\\.010046294958561372\ \(0\)\
\-\ an\\:\\ 0\\.009971855394807846\ \(0\)\
\-\ lobe\\:\\ 0\\.009701794716976936\ \(0\)\
\-\ lesions\\:\\ 0\\.00965215403520653\ \(0\)\
\-\ mild\\:\\ 0\\.009494740311945724\ \(0\)\
\-\ evidence\\:\\ 0\\.009453344233615516\ \(0\)\
\-\ \\(\\:\\ 0\\.009143819319542537\ \(0\)\
\-\ 1\\:\\ 0\\.008579436151728721\ \(0\)\
\-\ woman\\:\\ 0\\.008328704419784413\ \(0\)\
\-\ lower\\:\\ 0\\.008109122655543723\ \(0\)\
\-\ contrast\\:\\ 0\\.00807078348864095\ \(0\)\
\-\ \\,\\:\\ 0\\.007995655943548572\ \(0\)\
\-\ 2\\:\\ 0\\.0077641539937153845\ \(0\)\
\-\ patient\\:\\ 0\\.007228623889589772\ \(0\)\
\-\ which\\:\\ 0\\.0067305678786605426\ \(0\)\
\-\ the\\:\\ 0\\.0064166334672568935\ \(0\)\
\-\ normal\\:\\ 0\\.0056523732261565445\ \(0\)\
\-\ there\\:\\ 0\\.005365888423902905\ \(0\)\
\-\ and\\:\\ 0\\.005316721688293372\ \(0\)\
\-\ not\\:\\ 0\\.005210205365999727\ \(0\)\
\-\ ct\\:\\ 0\\.005043475330768113\ \(0\)\
\-\ history\\:\\ 0\\.004979808175979254\ \(0\)\
\-\ of\\:\\ 0\\.004915772185569132\ \(0\)\
\-\ are\\:\\ 0\\.004915079630926589\ \(0\)\
\-\ at\\:\\ 0\\.0048850765942263\ \(0\)\
\-\ left\\:\\ 0\\.0040341994484089224\ \(0\)\
\-\ year\\:\\ 0\\.0040341994484089224\ \(0\)\
\-\ old\\:\\ 0\\.003691707159756348\ \(0\)\
\-\ no\\:\\ 0\\.0036305660367249026\ \(0\)\
\-\ for\\:\\ 0\\.003076405690475591\ \(0\)\
\-\ \\.\\:\\ 0\\.0019472319378291208\ \(0\)\
\-\ in\\:\\ 0\\.0017780473845580376\ \(0\)\
\-\ a\\:\\ 0\\.0016734168853105537\ \(0\)\
\-\ with\\:\\ 0\\.0014810655201251866\ \(0\)\
